v3.26.3
Equity - Schedule of Warrants Outstanding (Details)
Jun. 30, 2026
$ / shares
shares
Exercise Prices One [Member]  
Schedule of Warrants Outstanding [Line Items]  
Number of Warrants 238,096
Exercise Price Per Share | $ / shares $ 21
Issuance date May 29, 2024
Expiration date Nov. 29, 2029 [1]
Exercise Prices Two [Member]  
Schedule of Warrants Outstanding [Line Items]  
Number of Warrants 8,335
Exercise Price Per Share | $ / shares $ 26.25
Issuance date May 29, 2024
Expiration date May 27, 2029 [2]
Exercise Price Three [Member]  
Schedule of Warrants Outstanding [Line Items]  
Number of Warrants 1,667
Exercise Price Per Share | $ / shares $ 48.75
Issuance date Nov. 26, 2024
Expiration date Feb. 02, 2027
Exercise Price Four [Member]  
Schedule of Warrants Outstanding [Line Items]  
Number of Warrants 1,667
Exercise Price Per Share | $ / shares $ 63.75
Issuance date Nov. 26, 2024
Expiration date Feb. 02, 2027
Exercise Price Five [Member]  
Schedule of Warrants Outstanding [Line Items]  
Number of Warrants 116,667
Exercise Price Per Share | $ / shares $ 15
Issuance date Nov. 24, 2025
Expiration date Nov. 30, 2030
Exercise Price Six [Member]  
Schedule of Warrants Outstanding [Line Items]  
Number of Warrants 79,708
Exercise Price Per Share | $ / shares $ 0.015
Issuance date Nov. 24, 2025
Expiration date
Exercise Prices Seven [Member]  
Schedule of Warrants Outstanding [Line Items]  
Number of Warrants 46,375
Exercise Price Per Share | $ / shares $ 0.015
Issuance date Nov. 24, 2025
Expiration date
Exercise Prices Eight [Member]  
Schedule of Warrants Outstanding [Line Items]  
Number of Warrants 492,515
[1] The earlier of (a) November 29, 2029 and (b) the 60th day following the Company’s public announcement of its filing with the U.S. Food and Drug Administration for approval for AllocetraTM’s osteoarthritis related indication (the “Series B Milestone Event”).
[2] The earlier of (a) May 27, 2029 and (b) 60 days following the Series B Milestone Event.